Zymfentra (infliximab-dyyb subcutaneous) / Celltrion 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345678»
  • ||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Journal:  Combination treatment risankizumab and subcutaneous infliximab for refractory Crohn's disease. (Pubmed Central) -  Jan 12, 2025   
    The patient received different treatments with biologics withouth achieving response, so we decide to try combination therapy with subcutaneous Infliximab and Risakizumab. The patient showed improvement at second week, achieving both analytical, clinical and endoscopic response .
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Loss & Gain Productivity (LGP) of SC Infliximab: Preliminary Data Based on HEOR Model in LMIC/LATAM/Brazil () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_951;    
    Based on these ( the incidence of these pathologies, using the pharmacoeconomic model with application of results from the international scenario of costs to be avoided with the adoption of innovation ) , we conclude that it is dominant cost effectiveness for this situation. More detailed studies are needed to corroborate other economic advantages , even for to the loss & gain productivity .
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Journal:  A Practical Approach to Subcutaneous Infliximab. (Pubmed Central) -  Nov 4, 2024   
    More detailed studies are needed to corroborate other economic advantages , even for to the loss & gain productivity . No abstract available
  • ||||||||||  Stelara (ustekinumab) / J&J, Simponi (golimumab) / J&J, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    treatment regimes for cutaneous sarcoidosis: a meta-analysis of randomized double blind placebo controlled trials (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_4201;    
    Systemic agents like Infliximab showed promising results, but heterogeneity between outcome assessments and definition of treatment response hamper comparability between included studies. Treatment selection should consider the extent and severity of cutaneous and other organ involvement, patient comorbidities, as well as potential adverse effects.
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Enrollment open:  AMARETTO: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization (clinicaltrials.gov) -  Jul 25, 2024   
    P4,  N=275, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Jul 2024 Active, not recruiting --> Recruiting
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    FINANCIAL IMPLICATIONS OF FIXED DOSING OF SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1434;    
    There is a concern regarding the affordability of SC IFX because it is generally priced higher than IV IFX, which has many biosimilars on the market. However, this study asserts that fixed dosing of 120mg of IFX is cost-saving for society, considering highly prevalent practice of dose escalation and/or shortened intervals of IFX regimen.
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    RENAL GRANULOMATOSIS IN CROHN (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_878;    
    At one year, colonoscopy showed endoscopic remission, with ongoing improvement in renal function (creatinine 194 to 111 umol/L) and resolution of pyuria. In conclusion, we present a rare case of CD-associated interstitial nephritis, showing a positive clinical response to infliximab monotherapy.
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Enrollment closed:  AMARETTO: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization (clinicaltrials.gov) -  Apr 28, 2024   
    P4,  N=275, Active, not recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
  • ||||||||||  Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    Enrollment closed, Enrollment change, Trial primary completion date:  SIC2: Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease (clinicaltrials.gov) -  Mar 25, 2024   
    P=N/A,  N=22, Active, not recruiting, 
    IFX SC demonstrated better efficacy than VDZ in patients with CD, and similar efficacy to VDZ in patients with UC; 1-year safety was comparable with IFX SC and VDZ. Recruiting --> Active, not recruiting | N=170 --> 22 | Trial primary completion date: Aug 2024 --> Dec 2023
  • ||||||||||  Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
    5435: Uncontrolled Therapeutic Observations in IBD (Ballroom B - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_8147;    
    The SC formulation appears to be effective and safe for active pCD, and for maintaining remission in inactive pCD Description: In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis Learning Objectives: Describe the safety and efficacy of stem cells for perianal fistulas in Crohn's disease, Assess the safety and efficacy of subcutaneous infliximab, Describe the efficacy of small molecules for microscopic colitis